MarketCap
Facebook
X
Telegram
Tenax Therapeutics Operating Cash Flow | TENX
Annual Operating Cash Flow Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.8 M | -14.8 M | -5.9 M | -11.4 M | -10.9 M | -9.27 M | -7.56 M | -5.5 M | -12.1 M | -15.9 M | -9.75 M | -9.26 M | -4.92 M | -8.28 M | -8.4 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.92 M | -35.8 M | -11.3 M |
Quarterly Operating Cash Flow Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.5 M | -9.31 M | - | - | -6.97 M | - | - | - | -5.17 M | - | - | - | -1.72 M | - | -9.7 M | -6.37 M | -2.94 M | - | -8.09 M | -5.07 M | -3.22 M | - | -7.29 M | -4.9 M | -2.67 M | - | -5.83 M | -4.05 M | -2.13 M | - | -4.3 M | -2.75 M | -1.56 M | - | -10.9 M | -9.63 M | -4.04 M | - | -12.8 M | -8.49 M | -3.32 M | - | -8.47 M | -6.54 M | -2.54 M | - | -6.28 M | -4.89 M | -1.98 M | - | -3.48 M | -3.58 M | -1.56 M | - | -6.86 M | -2.74 M | -1.61 M | - | -6.65 M | -4.58 M | -2.05 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.56 M | -23.5 M | -5.62 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Neurocrine Biosciences
NBIX
|
783 M | $ 145.91 | 2.25 % | $ 14.5 B |  USA |
 |
Orgenesis
ORGS
|
-17.1 M | - | -33.86 % | $ 61.2 M | USA |
 |
Biogen
BIIB
|
2.2 B | $ 252.25 | 0.62 % | $ 37 B | USA |
 |
Minerva Neurosciences
NERV
|
-13.5 M | $ 2.2 | -4.35 % | $ 18.6 M | USA |
 |
Nektar Therapeutics
NKTR
|
-209 M | $ 37.17 | -0.12 % | $ 627 M | USA |
 |
Nkarta
NKTX
|
-88.7 M | $ 1.87 | 4.47 % | $ 138 M | USA |
 |
NanoViricides
NNVC
|
-7.7 M | $ 1.37 | -2.14 % | $ 27.7 M | USA |
 |
Codiak BioSciences
CDAK
|
-74.1 M | - | -55.98 % | $ 2.15 M | USA |
 |
Nurix Therapeutics
NRIX
|
-249 M | $ 25.55 | 0.83 % | $ 2.21 B | USA |
 |
Kodiak Sciences
KOD
|
-136 M | $ 89.5 | 2.13 % | $ 4.76 B | USA |
 |
Intellia Therapeutics
NTLA
|
-395 M | $ 11.26 | 0.4 % | $ 1.22 B | USA |
 |
Novavax
NVAX
|
-245 M | $ 9.4 | -3.14 % | $ 1.52 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-8.07 M | $ 2.01 | -1.47 % | $ 4.96 B |  Israel |
 |
Bristol-Myers Squibb Company
BMY
|
14.2 B | $ 61.57 | 0.15 % | $ 125 B | USA |
 |
Novartis AG
NVS
|
19.1 B | $ 153.93 | 1.86 % | $ 298 B |  Schweiz |
 |
NextCure
NXTC
|
-49.6 M | $ 5.22 | 4.72 % | $ 14.8 M | USA |
 |
Ocugen
OCGN
|
-57 M | $ 0.71 | -4.64 % | $ 222 M | USA |
 |
Ocular Therapeutix
OCUL
|
-205 M | $ 6.49 | -0.23 % | $ 1.22 B | USA |
 |
Oragenics
OGEN
|
-9.25 M | $ 0.4 | -3.86 % | $ 863 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Omeros Corporation
OMER
|
-116 M | $ 16.27 | -1.81 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-111 M | $ 8.99 | -31.74 % | $ 789 M | USA |
 |
Oramed Pharmaceuticals
ORMP
|
-9.14 M | $ 4.08 | -1.21 % | $ 169 M | Israel |
 |
Outlook Therapeutics
OTLK
|
-51.8 M | $ 0.51 | -1.71 % | $ 17.7 M | USA |
 |
Ovid Therapeutics
OVID
|
-38.3 M | $ 2.15 | -0.23 % | $ 280 M | USA |
 |
Sage Therapeutics
SAGE
|
-267 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
31.8 M | - | - | $ 1.62 B | Israel |
 |
Nuvation Bio
NUVB
|
-173 M | $ 4.5 | -1.53 % | $ 1.54 B | USA |
 |
Puma Biotechnology
PBYI
|
41.8 M | $ 10.85 | -1.54 % | $ 543 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
-11.4 M | $ 1.76 | -2.76 % | $ 2.3 M | USA |
 |
Vaxcyte
PCVX
|
-656 M | $ 59.95 | -0.79 % | $ 8.16 B | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-150 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-193 M | - | - | $ 8.14 B | USA |
 |
Pfizer
PFE
|
11.7 B | $ 29.8 | -0.78 % | $ 169 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
1.26 B | - | - | $ 26.6 B |  Irlanda |
 |
Pharming Group N.V.
PHAR
|
74 M | $ 11.85 | 5.8 % | $ 8.16 B |  Niderland |
|
Phathom Pharmaceuticals
PHAT
|
-167 M | $ 5.94 | 3.48 % | $ 433 M | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
-7.98 M | $ 0.87 | 2.04 % | $ 5.21 M | USA |
 |
Lantern Pharma
LTRN
|
-15.7 M | $ 0.6 | -5.34 % | $ 6.54 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-66.1 M | - | - | $ 121 M | USA |
 |
Pliant Therapeutics
PLRX
|
-128 M | $ 0.85 | -1.64 % | $ 52.2 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-46.6 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-20.9 M | - | -33.41 % | $ 3.37 M | USA |
 |
Praxis Precision Medicines
PRAX
|
-249 M | $ 267.68 | 5.82 % | $ 6.02 B | USA |
 |
PainReform Ltd.
PRFX
|
-3.96 M | $ 0.74 | 0.07 % | $ 480 K | Israel |
 |
Prelude Therapeutics Incorporated
PRLD
|
-56.3 M | $ 3.69 | 1.65 % | $ 284 M | USA |
 |
iTeos Therapeutics
ITOS
|
-98.2 M | - | - | $ 411 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-52.8 M | $ 1.23 | -4.65 % | $ 130 M | Niderland |